Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC1A3 antisense RNA 1 (SLC1A3-AS1)
- Target
- SLC1A3-AS1
- Molecular classification
- Other (long noncoding RNA)
01
Overview
SLC1A3 antisense RNA 1 (SLC1A3-AS1) is a human long noncoding RNA transcribed from the SLC1A3 locus. It is not a protein-coding gene, but instead functions in gene regulation, particularly as a competitive endogenous RNA (ceRNA) by sequestering specific microRNAs (e.g., miR-486-5p), resulting in the upregulation of genes such as E2F transcription factor 6. SLC1A3-AS1 is overexpressed in certain cancers, including nasopharyngeal carcinoma, and its elevated levels correlate with increased tumor aggressiveness and poorer patient outcomes[2]. There is no evidence that it acts as a transporter, receptor, enzyme, or transcription factor, and it is not a recognized drug target[2]. If you intended to refer to SLC1A3 (solute carrier family 1 member 3), which is a well-studied aspartate/glutamate transporter protein, that is a distinct target and should not be confused with SLC1A3-AS1[1][3].
- Other names
- AC008957.1CTD-2353F22.1SLC1A3-AS1
02
Biological functions
Gene regulation (functions as a competitive endogenous RNA, or ceRNA, modulating the effects of microRNAs on target gene translation[2])
03
Disease associations
Cancer (nasopharyngeal carcinoma; associated with poorer prognosis and increased tumor cell proliferation, migration, invasion, and reduced apoptosis[2])
04
Biomarkers
High SLC1A3-AS1 expression is associated with poor prognosis in nasopharyngeal carcinoma patients[2]
Beyond the preview
Go deeper on SLC1A3 antisense RNA 1 (SLC1A3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC1A3 antisense RNA 1 (SLC1A3-AS1).